Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX), a leading global medical technology company, has announced its upcoming 2025 Annual Meeting of Shareholders, which will be held virtually on Tuesday, January 28, 2025, at 1:00 p.m. (ET).

Shareholders of record as of December 9, 2024, or their authorized proxies, will have full participation rights, including the ability to attend, vote, and ask questions during the meeting by accessing the provided virtual platform at https://meetnow.global/M5X7D4A. Guests can also attend in listen-only mode without requiring a control number.

The company will make a replay of the webcast available on the BD website at investors.bd.com for approximately one year following the Annual Meeting.

BD (NYSE: BDX) and Babson Diagnostics announced an expansion of their fingertip blood collection and testing technologies for U.S. health systems and provider networks. The innovation combines BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies, requiring only six drops of blood from a finger prick. The system can be operated by any trained healthcare worker without phlebotomy experience.

This development aims to improve access to blood testing in underserved locations and reduce barriers like needle fear and logistical challenges. The partnership, which began in 2016, has already implemented BetterWay blood testing in retail settings since May 2024 and is now expanding to ambulatory care sites across the United States.

BD (BDX) has reached a settlement with the SEC regarding an investigation into previous disclosures about the BD Alaris™ System, acquired from CareFusion in 2015. The company will pay $175 million to resolve the matter, an amount already reserved and disclosed in their FY2024 Form 10-K. The settlement, which involves events from over four years ago, requires no financial restatements and won't affect BD's innovation investments or capital allocation strategy.

The company maintains that the BD Alaris™ System is safe and effective, noting its critical role in healthcare delivery, including during the COVID-19 pandemic. The system received FDA 510(k) clearance in July 2023. BD has implemented improvements to its operational and governance processes, affirming its commitment to ethical standards and product quality.

Vantage Point Logistics (VPL) has appointed Mark Longley as its new Chief Executive Officer, while Co-Founder Eric McGlade transitions to Chairman of the Board. Longley, with over 20 years of healthcare technology experience, joins VPL from Parata Systems, where he served as Chief Commercial Officer and General Manager. At Parata, he led sales, marketing, and strategy operations, playing a important role in the company's successful sale to Becton, Dickinson and Company (BDX). VPL, a clinical supply chain technology company, has experienced rapid growth and established itself as a trusted partner in integrating technology with freight management and pharmacy workflows.

A groundbreaking HPV self-collection screening pilot program has launched in Texas to improve cervical cancer screening in underserved communities. The study, conducted at Su Clinica in partnership with MD Anderson Cancer Center, utilizes the BD Onclarity™ HPV Assay (NYSE: BDX), recently FDA-approved for HPV self-collection screening. The initiative, supported by a $2.5 million CPRIT grant, aims to evaluate implementation effectiveness and develop scalable best practices for nationwide application. The program specifically targets communities facing healthcare barriers, offering bilingual options and financial support for uninsured patients.

BD (NYSE: BDX), a leading global medical technology company, announced its upcoming presentation at the 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 10:50 am Eastern Time.

Interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay will be made available on the same webpage after the presentation concludes.

BD (BDX) reported strong Q4 and FY2024 results with Q4 revenue reaching $5.4 billion, up 6.9% as reported. Fourth quarter GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4% to $1.45 and $3.81 respectively. Full-year revenue reached $20.2 billion, with organic growth of 5.0%. FY2024 cash from continuing operations increased 28.5% to $3.8 billion, while Free Cash Flow grew 47.4% to $3.1 billion. The company provided FY2025 guidance projecting organic growth of 4.0% to 4.5% and adjusted diluted EPS growth of approximately 10% at midpoint.

BD (NYSE: BDX) has announced a 9.5% increase in its quarterly dividend to $1.04 per common share, payable on December 31, 2024, to shareholders of record on December 9, 2024. This marks the company's 53rd consecutive year of dividend increases, maintaining its position in the S&P 500 Dividend Aristocrats Index. The indicated annual dividend rate for fiscal year 2025 is set at $4.16 per share. Management attributes this increase to confidence in their long-term outlook and commitment to shareholder value through their BD 2025 strategy.

BD (NYSE: BDX) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in emergency situations where IV access is challenging. The system features unique advantages including placement capability after extension set attachment and integrated passive needle tip safety. The device offers five needle length options and includes a rechargeable battery that lasts up to 12 times longer than competitors'. Clinical studies show trained users achieve a 93-97% success rate in IO placement, with less than 1% chance of serious complications. The system is now available in the U.S. market.